Diagnosis and Treatment of Parkinson Disease: A Review - PubMed (original) (raw)
Review
. 2020 Feb 11;323(6):548-560.
doi: 10.1001/jama.2019.22360.
Affiliations
- PMID: 32044947
- DOI: 10.1001/jama.2019.22360
Review
Diagnosis and Treatment of Parkinson Disease: A Review
Melissa J Armstrong et al. JAMA. 2020.
Abstract
Importance: Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like movement problems such as rigidity, slowness, and tremor. More than 6 million individuals worldwide have Parkinson disease.
Observations: Diagnosis of Parkinson disease is based on history and examination. History can include prodromal features (eg, rapid eye movement sleep behavior disorder, hyposmia, constipation), characteristic movement difficulty (eg, tremor, stiffness, slowness), and psychological or cognitive problems (eg, cognitive decline, depression, anxiety). Examination typically demonstrates bradykinesia with tremor, rigidity, or both. Dopamine transporter single-photon emission computed tomography can improve the accuracy of diagnosis when the presence of parkinsonism is uncertain. Parkinson disease has multiple disease variants with different prognoses. Individuals with a diffuse malignant subtype (9%-16% of individuals with Parkinson disease) have prominent early motor and nonmotor symptoms, poor response to medication, and faster disease progression. Individuals with mild motor-predominant Parkinson disease (49%-53% of individuals with Parkinson disease) have mild symptoms, a good response to dopaminergic medications (eg, carbidopa-levodopa, dopamine agonists), and slower disease progression. Other individuals have an intermediate subtype. For all patients with Parkinson disease, treatment is symptomatic, focused on improvement in motor (eg, tremor, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs and symptoms. No disease-modifying pharmacologic treatments are available. Dopamine-based therapies typically help initial motor symptoms. Nonmotor symptoms require nondopaminergic approaches (eg, selective serotonin reuptake inhibitors for psychiatric symptoms, cholinesterase inhibitors for cognition). Rehabilitative therapy and exercise complement pharmacologic treatments. Individuals experiencing complications, such as worsening symptoms and functional impairment when a medication dose wears off ("off periods"), medication-resistant tremor, and dyskinesias, benefit from advanced treatments such as therapy with levodopa-carbidopa enteral suspension or deep brain stimulation. Palliative care is part of Parkinson disease management.
Conclusions and relevance: Parkinson disease is a heterogeneous disease with rapidly and slowly progressive forms. Treatment involves pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and nonpharmacologic approaches (such as exercise and physical, occupational, and speech therapies). Approaches such as deep brain stimulation and treatment with levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremor, worsening symptoms when the medication wears off, and dyskinesias.
Similar articles
- Parkinson Disease.
Halli-Tierney AD, Luker J, Carroll DG. Halli-Tierney AD, et al. Am Fam Physician. 2020 Dec 1;102(11):679-691. Am Fam Physician. 2020. PMID: 33252908 - Parkinson's Disease.
Reich SG, Savitt JM. Reich SG, et al. Med Clin North Am. 2019 Mar;103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3. Med Clin North Am. 2019. PMID: 30704685 Review. - Pharmacological treatment of Parkinson disease: a review.
Connolly BS, Lang AE. Connolly BS, et al. JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654. JAMA. 2014. PMID: 24756517 Review. - Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F, Marconi S. Stocchi F, et al. Clin Neuropharmacol. 2010 Jul;33(4):198-203. doi: 10.1097/WNF.0b013e3181de8924. Clin Neuropharmacol. 2010. PMID: 20414107 Review. - Parkinson's disease: making the diagnosis, selecting drug therapies.
Scharre DW, Mahler ME. Scharre DW, et al. Geriatrics. 1994 Oct;49(10):14-6, 20-3. Geriatrics. 1994. PMID: 7926845
Cited by
- Anti-Inflammatory and Neuroprotective Effects of Morin in an MPTP-Induced Parkinson's Disease Model.
Hong DG, Lee S, Kim J, Yang S, Lee M, Ahn J, Lee H, Chang SC, Ha NC, Lee J. Hong DG, et al. Int J Mol Sci. 2022 Sep 12;23(18):10578. doi: 10.3390/ijms231810578. Int J Mol Sci. 2022. PMID: 36142491 Free PMC article. - The potential of arts therapies in Parkinson's disease rehabilitation: A comprehensive review.
Li Y, Luo X, Zhang A, Ying F, Wang J, Huang G. Li Y, et al. Heliyon. 2024 Aug 3;10(16):e35765. doi: 10.1016/j.heliyon.2024.e35765. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39229526 Free PMC article. Review. - Initial clinical evidence on biperiden as antiepileptogenic after traumatic brain injury-a randomized clinical trial.
Foresti ML, Garzon E, de Moraes MT, Valeriano RPS, Santiago JP, Dos Santos GM, Longo NM, Baise C, Andrade JCQF, Susemihl MA, Leite CDC, Naffah Mazzacoratti MDG, Paiva WS, de Andrade AF, Teixeira MJ, Mello LE. Foresti ML, et al. Front Neurol. 2024 Aug 7;15:1443982. doi: 10.3389/fneur.2024.1443982. eCollection 2024. Front Neurol. 2024. PMID: 39175759 Free PMC article. - Molecular Mechanisms Underlying the Beneficial Effects of Exercise on Brain Function and Neurological Disorders.
Nay K, Smiles WJ, Kaiser J, McAloon LM, Loh K, Galic S, Oakhill JS, Gundlach AL, Scott JW. Nay K, et al. Int J Mol Sci. 2021 Apr 14;22(8):4052. doi: 10.3390/ijms22084052. Int J Mol Sci. 2021. PMID: 33919972 Free PMC article. Review. - Efficacy and safety of 3-n-butylphthalide for the treatment of cognitive impairment: A systematic review and meta-analysis.
Zhou Q, Han C, Xia Y, Wan F, Yin S, Li Y, Kou L, Chi X, Hu J, Sun Y, Wu J, Zou W, Huang J, Wang T. Zhou Q, et al. CNS Neurosci Ther. 2022 Nov;28(11):1706-1717. doi: 10.1111/cns.13952. Epub 2022 Sep 1. CNS Neurosci Ther. 2022. PMID: 36047338 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical